Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Blood Glucose Control Improved by Ultra-fast Acting Insulin: Lilly Symposium
August 6, 2001
- Nippon Kayaku to Place Top Priority on R&D
August 6, 2001
- Large Studies Required to Verify Inhibition of Cardiovascular Events: Sankyo Seminar
August 6, 2001
- Shimadzu: HPLC Autosampler SIL-HT
July 30, 2001
- Asahi Glass Ties Up with DMS Biologics to Contract to Manufacture Biotechnology Drugs
July 30, 2001
- Industry FTC to Prohibit Free Loan of Medical Devices
July 30, 2001
- Tanabe Licenses Bepotastine to Senju as Eye Drop
July 30, 2001
- Differences in Prices of Catheters in Japan, Abroad Highlighted: JSIC Meeting
July 30, 2001
- Makers Accelerating Business Restructuring
July 30, 2001
- WORLD NEWS IN BRIEF
July 30, 2001
- Drug Dispensing Cost Outstrips Dental Care Cost
July 30, 2001
- JST Select 10 Research Themes to Support in FY2001
July 30, 2001
- 5 Products Including NovoRapid, Isuhuman, Flutide Recommended for Approval
July 30, 2001
- Glivec Highly Effective against CML: Novartis Seminar
July 30, 2001
- Stomach Cancer to Be Approved as New Indication for Taxol
July 30, 2001
- Risperdal Effective for Positive Symptoms of Schizophrenia: Dr Grogg of Janssen
July 30, 2001
- World Anti-cancer Market to Expand to \3 Trillion in 2005: Consultant
July 30, 2001
- Int'l Study on Rofecoxib in OA Patients Begins: Banyu, Merck
July 30, 2001
- Kyowa Hakko Enters PI in Europe for Anti-asthma KW-4490
July 30, 2001
- Only 5% of Migraine Sufferers Seek Professional Help: GSK Seminar
July 30, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…